Epitalon is a synthetic AEDG tetrapeptide studied as a claimed telomerase activator.

In plain English

Epitalon is a small lab-made peptide — a chain of four amino acids written as Ala-Glu-Asp-Gly, or AEDG for short. A peptide is just a short protein. Researchers have studied it as a claimed geroprotector (something tested for slowing aging in lab models) and as a possible switch for telomerase — the enzyme that rebuilds the protective caps on the ends of our chromosomes, which normally wear down as cells divide.

Here is the honest part. Most of the headline claims — longer telomeres, longer lifespan, anti-aging — come from one research group in Russia, and independent labs elsewhere have only begun to repeat the work in 2024 and 2025. Epitalon is not approved as a medicine anywhere in the US, Europe, or the UK. It is sold and handled as a research chemical, not a supplement. People in longevity communities report better sleep, but many report nothing at all — and what people report, including the downsides, is on the effects page.

What the Epitalon literature actually shows

Epitalon (also spelled Epithalon) is the tetrapeptide Ala-Glu-Asp-Gly — four amino acids, a molecular weight of 390.35 Da, formula C14H22N4O9, CAS 307297-39-8. It was derived from epithalamin, a peptide preparation extracted from the bovine pineal gland, and represents the short active sequence of that parent material.

The single most-cited finding is from cell culture: adding the peptide to telomerase-negative human fetal fibroblasts induced expression of the catalytic telomerase subunit (hTERT), restored telomerase activity, and elongated telomeres ^[1]. A later report described human somatic cells exceeding the Hayflick limit — the normal ceiling on how many times a cell divides — after the same treatment ^[7]. These are real, published results. They are also in vitro, and they originate, like most of the record, from one laboratory.

The affirmative animal data are specific. In female SHR mice, the peptide at 1.0 ug/mouse subcutaneously (five days a month from three months of age) raised maximum lifespan by 12.3% and reduced leukemia six-fold, without raising total tumor incidence ^[3]. Each of those numbers maps to a numbered citation on the Epitalon references page.

Single-source evidence

The central caveat for Epitalon is provenance. Nearly all of the foundational evidence — the original human-cell telomerase result, the rodent lifespan studies, the human cohort data — comes from Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology ^[2]. Independent, non-Russian replication of the core telomere claim was sparse until 2024-2025. The 2025 review in International Journal of Molecular Sciences summarizes the proposed mechanisms while noting that physico-chemical and structural characterization of the peptide remains limited ^[4]. Throughout this site the telomerase, telomere-lengthening, and lifespan claims are presented as claims and as single-group or animal findings — not as established human fact.

The melatonin axis and the second mechanism

Beyond telomeres, Epitalon is studied for a second, separate effect: the melatonin pathway. In rat pinealocyte culture, the peptide stimulated AANAT (arylalkylamine N-acetyltransferase, the rate-limiting enzyme that makes melatonin) and the transcription factor pCREB, and raised melatonin in the culture medium ^[6]. This is the basis for the circadian-normalization framing — the idea that the peptide nudges an age-shifted day-night hormone cycle back toward a younger pattern. The epitalon telomerase page covers the telomere mechanism in depth; the research page covers both. The distinction between Epitalon and its parent preparation epithalamin is covered on the epitalon peptide page.

How this reference is organized

This is an independent editorial digest of the peer-reviewed literature on Epitalon. It is organized as a technical record: the research page sets out the mechanism and the key studies; the dosage page covers research-context doses, routes, and the unmeasured half-life; the effects page covers what the research-use community reports and the cited safety cautions; the references page lists every source with its PMID and DOI. No purchase, no clinic, no prescription — the record, read soberly.